CD133作为肺癌干细胞标记物的应用及其局限性

Lung cancer is one of the most common tumor, which lacks of effective clinical treatment to lead to desirable prognosis. According to cancer stem cell hypothesis, lung cancer stem cells are considered to be responsible for carcinogenesis, development, metastasis, recurrence, invasion, resistance to...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2011
Materias:
综述
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999939/
https://www.ncbi.nlm.nih.gov/pubmed/22008114
http://dx.doi.org/10.3779/j.issn.1009-3419.2011.10.10
_version_ 1783331561845817344
collection PubMed
description Lung cancer is one of the most common tumor, which lacks of effective clinical treatment to lead to desirable prognosis. According to cancer stem cell hypothesis, lung cancer stem cells are considered to be responsible for carcinogenesis, development, metastasis, recurrence, invasion, resistance to chemotherapy and radiotherapy of lung cancer. In recent years, more and more institutes used glycosylated CD133 epitopes to define, isolate, purify lung cancer stem cells. However, along with deeply research, the application of CD133 epitopes in lung cancer stem cell research is questioned. The utilization and limitation of CD133 epitopes in lung cancer stem cells research for the past few years is summaried in this review.
format Online
Article
Text
id pubmed-5999939
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59999392018-07-06 CD133作为肺癌干细胞标记物的应用及其局限性 Zhongguo Fei Ai Za Zhi 综述 Lung cancer is one of the most common tumor, which lacks of effective clinical treatment to lead to desirable prognosis. According to cancer stem cell hypothesis, lung cancer stem cells are considered to be responsible for carcinogenesis, development, metastasis, recurrence, invasion, resistance to chemotherapy and radiotherapy of lung cancer. In recent years, more and more institutes used glycosylated CD133 epitopes to define, isolate, purify lung cancer stem cells. However, along with deeply research, the application of CD133 epitopes in lung cancer stem cell research is questioned. The utilization and limitation of CD133 epitopes in lung cancer stem cells research for the past few years is summaried in this review. 中国肺癌杂志编辑部 2011-10-20 /pmc/articles/PMC5999939/ /pubmed/22008114 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.10.10 Text en 版权所有©《中国肺癌杂志》编辑部2011 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 综述
CD133作为肺癌干细胞标记物的应用及其局限性
title CD133作为肺癌干细胞标记物的应用及其局限性
title_full CD133作为肺癌干细胞标记物的应用及其局限性
title_fullStr CD133作为肺癌干细胞标记物的应用及其局限性
title_full_unstemmed CD133作为肺癌干细胞标记物的应用及其局限性
title_short CD133作为肺癌干细胞标记物的应用及其局限性
title_sort cd133作为肺癌干细胞标记物的应用及其局限性
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999939/
https://www.ncbi.nlm.nih.gov/pubmed/22008114
http://dx.doi.org/10.3779/j.issn.1009-3419.2011.10.10

Ejemplares similares